

# **Asia Pacific Osteoporosis Drugs Market By Route of Administration (Oral, Injectable and Other Route of Administration) By Drug Class (Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes) By Country, Industry Analysis and Forecast, 2020 - 2026**

<https://marketpublishers.com/r/A2015DDB686FEN.html>

Date: May 2020

Pages: 79

Price: US\$ 1,500.00 (Single User License)

ID: A2015DDB686FEN

## **Abstracts**

The Asia Pacific Osteoporosis Drugs Market would witness market growth of 5.6% CAGR during the forecast period (2020-2026).

The Asia Pacific market is expected to rise in the coming years in a lucrative CAGR. The region's rapid growth is expected to be a result of steady R&D spending by the prominent actors and their attempts to market branded and generic medicine at a reasonably low price. The industry is expected to witness intense competition during the forecast period as a result of the increasing incorporation of collaborative strategies among key players to maintain a competitive position. High R&D investment, fusions, and acquisitions, and drug development agreements are the other strategies incorporated.

There has been a noticeable growth in people around the world's awareness of osteoporosis, which is a noticeable factor in the osteoporosis market. This recognition is primarily a result of numerous steps implemented across different programs and campaigns by public and private associations. For example, the International Foundation for Osteoporosis is an osteoporosis organization.

Due to the increase in R&D investment from major players in advanced novel

bisphosphonate drugs, bisphosphonates acquired the major share in the osteoporosis market. Bisphosphonates are also widely used osteoporosis drugs, which stimulates market growth. However, the rank ligand inhibitor segment is expected to have the fastest growth rate during the forecast period, due to the fact that these drugs are used to treat bone metastases by acting as a chemoattractant to the bone for tumor cells that express its receptor, RANK. The RANKL-RANK pathway inhibition thus acts as an ideal treatment for bone metastasis.

Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company

## Scope of the Study

### Market Segmentation:

#### By Route of Administration

Oral

Injectable and

Other Route of Administration

#### By Drug Class

Bisphosphonates

Rank Ligand Inhibitors

Parathyroid Hormone Therapy

Calcitonin

Selective Estrogen Inhibitors Modulator (SERM) and

Other Drug Classes

### By Country

China

Japan

India

South Korea

Singapore

Malaysia

Rest of Asia Pacific

### Companies Profiled

Amgen, Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline PLC (GSK)

Merck & Co., Inc.

Novartis AG

Pfizer, Inc.

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceuticals Industries Ltd.

Allergan PLC

Eli Lilly and Company

### Unique Offerings from KBV Research

Exhaustive coverage

Highest number of market tables and figures

Subscription based model available

Guaranteed best price

Assured post sales research support with 10% customization free

## Contents

### **CHAPTER 1. MARKET SCOPE & METHODOLOGY**

- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
  - 1.4.1 Asia Pacific Osteoporosis Drugs Market, by Route of Administration
  - 1.4.2 Asia Pacific Osteoporosis Drugs Market, by Drug Class
  - 1.4.3 Asia Pacific Osteoporosis Drugs Market, by Country
- 1.5 Methodology for the research

### **CHAPTER 2. MARKET OVERVIEW**

- 2.1 Introduction
  - 2.1.1 Overview
  - 2.1.2 Market Composition and Scenario
- 2.2 Key Factors Impacting the Market
  - 2.2.1 Market Drivers
  - 2.2.2 Market Restraints

### **CHAPTER 3. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION**

- 3.1 Asia Pacific Oral Market by Country
- 3.2 Asia Pacific Injectable Market by Country
- 3.3 Asia Pacific Other Route of Administration Market by Country

### **CHAPTER 4. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS**

- 4.1 Asia Pacific Bisphosphonates Market by Country
- 4.2 Asia Pacific Rank Ligand Inhibitors Market by Country
- 4.3 Asia Pacific Parathyroid Hormone Therapy Market by Country
- 4.4 Asia Pacific Calcitonin Market by Country
- 4.5 Asia Pacific Other Drug Class Market by Country

### **CHAPTER 5. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY COUNTRY**

- 5.1 China Osteoporosis Drugs Market
  - 5.1.1 China Osteoporosis Drugs Market by Route of Administration
  - 5.1.2 China Osteoporosis Drugs Market by Drug Class
- 5.2 India Osteoporosis Drugs Market
  - 5.2.1 India Osteoporosis Drugs Market by Route of Administration
  - 5.2.2 India Osteoporosis Drugs Market by Drug Class
- 5.3 Japan Osteoporosis Drugs Market
  - 5.3.1 Japan Osteoporosis Drugs Market by Route of Administration
  - 5.3.2 Japan Osteoporosis Drugs Market by Drug Class
- 5.4 South Korea Osteoporosis Drugs Market
  - 5.4.1 South Korea Osteoporosis Drugs Market by Route of Administration
  - 5.4.2 South Korea Osteoporosis Drugs Market by Drug Class
- 5.5 Singapore Osteoporosis Drugs Market
  - 5.5.1 Singapore Osteoporosis Drugs Market by Route of Administration
  - 5.5.2 Singapore Osteoporosis Drugs Market by Drug Class
- 5.6 Malaysia Osteoporosis Drugs Market
  - 5.6.1 Malaysia Osteoporosis Drugs Market by Route of Administration
  - 5.6.2 Malaysia Osteoporosis Drugs Market by Drug Class
- 5.7 Rest of Asia Pacific Osteoporosis Drugs Market
  - 5.7.1 Rest of Asia Pacific Osteoporosis Drugs Market by Route of Administration
  - 5.7.2 Rest of Asia Pacific Osteoporosis Drugs Market by Drug Class

## **CHAPTER 6. COMPANY PROFILES**

- 6.1 Amgen, Inc.
  - 6.1.1 Company Overview
  - 6.1.2 Financial Analysis
  - 6.1.3 Research & Development Expense
  - 6.1.4 Recent strategies and developments:
    - 6.1.4.1 Partnerships, Collaborations, and Agreements:
    - 6.1.4.2 Approvals:
- 6.2 F. Hoffmann-La Roche Ltd.
  - 6.2.1 Company Overview
  - 6.2.2 Financial Analysis
  - 6.2.3 Segmental and Regional Analysis
  - 6.2.4 Research & Development Expense
- 6.3 GlaxoSmithKline PLC (GSK)
  - 6.3.1 Company Overview
  - 6.3.2 Financial Analysis

- 6.3.3 Segmental and Regional Analysis
- 6.3.4 Research & Development Expense
- 6.4 Merck & Co., Inc.
  - 6.4.1 Company Overview
  - 6.4.2 Financial Analysis
  - 6.4.3 Segmental and Regional Analysis
  - 6.4.4 Research & Development Expenses
- 6.5 Novartis AG
  - 6.5.1 Company Overview
  - 6.5.2 Financial Analysis
  - 6.5.3 Segmental and Regional Analysis
  - 6.5.4 Recent strategies and developments:
    - 6.5.4.1 Partnerships, Collaborations, and Agreements:
- 6.6 Pfizer, Inc.
  - 6.6.1 Company Overview
  - 6.6.2 Financial Analysis
  - 6.6.3 Segmental and Regional Analysis
  - 6.6.4 Research & Development Expense
- 6.7 Sun Pharmaceutical Industries Ltd.
  - 6.7.1 Company Overview
  - 6.7.2 Financial Analysis
  - 6.7.3 Regional Analysis
  - 6.7.4 Research & Development Expense
- 6.8 Teva Pharmaceutical Industries Ltd.
  - 6.8.1 Company Overview
  - 6.8.2 Financial Analysis
  - 6.8.3 Regional Analysis
  - 6.8.4 Research & Development Expenses
- 6.9 Allergan PLC
  - 6.9.1 Company Overview
  - 6.9.2 Financial Analysis
  - 6.9.3 Segmental and Regional Analysis
  - 6.9.4 Research & Development Expense
- 6.1 Eli Lilly and Company
  - 6.10.1 Company Overview
  - 6.10.2 Financial Analysis
  - 6.10.3 Regional Analysis
  - 6.10.4 Research & Development Expense

## List Of Tables

### LIST OF TABLES

TABLE 1 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 2 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 3 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 4 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 5 ASIA PACIFIC ORAL MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 6 ASIA PACIFIC ORAL MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 7 ASIA PACIFIC INJECTABLE MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 8 ASIA PACIFIC INJECTABLE MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 9 ASIA PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 10 ASIA PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 11 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION

TABLE 12 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION

TABLE 13 ASIA PACIFIC BISPHOSPHONATES MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 14 ASIA PACIFIC BISPHOSPHONATES MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 15 ASIA PACIFIC RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 16 ASIA PACIFIC RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 17 ASIA PACIFIC PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 18 ASIA PACIFIC PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 19 ASIA PACIFIC CALCITONIN MARKET BY COUNTRY, 2016 - 2019, USD



MILLION

TABLE 20 ASIA PACIFIC CALCITONIN MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 21 ASIA PACIFIC OTHER DRUG CLASS MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 22 ASIA PACIFIC OTHER DRUG CLASS MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 23 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2016 - 2019, USD MILLION

TABLE 24 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2020 - 2026, USD MILLION

TABLE 25 CHINA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 26 CHINA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 27 CHINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 28 CHINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 29 CHINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION

TABLE 30 CHINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION

TABLE 31 INDIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 32 INDIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 33 INDIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 34 INDIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 35 INDIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION

TABLE 36 INDIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION

TABLE 37 JAPAN OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 38 JAPAN OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 39 JAPAN OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 40 JAPAN OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 41 JAPAN OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION

TABLE 42 JAPAN OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION

TABLE 43 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 44 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 45 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 46 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 47 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION

TABLE 48 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION

TABLE 49 SINGAPORE OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 50 SINGAPORE OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 51 SINGAPORE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 52 SINGAPORE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 53 SINGAPORE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION

TABLE 54 SINGAPORE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION

TABLE 55 MALAYSIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION

TABLE 56 MALAYSIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION

TABLE 57 MALAYSIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 58 MALAYSIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 59 MALAYSIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION

TABLE 60 MALAYSIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION

TABLE 61 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2016 - 2019,

USD MILLION

TABLE 62 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2020 - 2026,  
USD MILLION

TABLE 63 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE  
OF ADMINISTRATION, 2016 - 2019, USD MILLION

TABLE 64 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE  
OF ADMINISTRATION, 2020 - 2026, USD MILLION

TABLE 65 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG  
CLASS, 2016 - 2019, USD MILLION

TABLE 66 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG  
CLASS, 2020 - 2026, USD MILLION

TABLE 67 KEY INFORMATION – AMGEN, INC.

TABLE 68 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.

TABLE 69 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)

TABLE 70 KEY INFORMATION - MERCK & CO., INC.

TABLE 71 KEY INFORMATION – NOVARTIS AG

TABLE 72 KEY INFORMATION – PFIZER, INC.

TABLE 73 KEY INFORMATION – SUN PHARMACEUTICAL INDUSTRIES LTD.

TABLE 74 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.

TABLE 75 KEY INFORMATION – ALLERGAN PLC

TABLE 76 KEY INFORMATION – ELI LILLY AND COMPANY

## List Of Figures

### LIST OF FIGURES

FIG 1 METHODOLOGY FOR THE RESEARCH

## I would like to order

Product name: Asia Pacific Osteoporosis Drugs Market By Route of Administration (Oral, Injectable and Other Route of Administration) By Drug Class (Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes) By Country, Industry Analysis and Forecast, 2020 - 2026

Product link: <https://marketpublishers.com/r/A2015DDB686FEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A2015DDB686FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970